← Issue №17/ week of Oct 25, 2026/Pancreas/Biliary

Psychometric Validation of PROMIS Measures in Acute and Chronic Pancreatitis.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary prospective cohort · n=1,927 · Oct 22, 2026 · Clin Transl Gastro · IF 3.4

Psychometric Validation of PROMIS Measures in Acute and Chronic Pancreatitis.

New evidenceacute pancreatitischronic pancreatitis
Clinical takeawayConsider using PROMIS-29, PROMIS-Global Health, and PROMIS Pain Quality scales for consistent and reliable assessment of symptom burden and QoL in AP/CP patients in both clinical research and patient care.
What it foundPROMIS measures exceeded all psychometric benchmarks tested, including univariate construct validity, known-groups validity, convergent validity, reliability, structural validity, and population invariance across age, sex, race, and diagnostic subgroups in AP/CP patients.
ContextConfirms the suitability of PROMIS measures for AP/CP, addressing a gap in robust psychometric evidence for existing instruments in this population.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Askew RL … Consortium for the Study of Chronic Pancreatitis, Diabetes, Pancreatic Cancer (CPDPC) · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues